Mounjaro 2.5 mg: the starter dose, what it does and what it doesn't

The biggest myth: low dose means it isn't working

A question our prescribers hear most weeks is some version of: "I've been on 2.5 mg for three weeks and I haven't lost much, is it doing anything?" It's a fair thing to wonder. The honest answer is that 2.5 mg tirzepatide is not designed to produce the weight loss you read about in trial results. Those figures (around 20% average body-weight reduction at the highest doses in the SURMOUNT-1 trial, published in the New England Journal of Medicine) come from months of treatment at doses of 10 mg and 15 mg. The starter dose exists for one specific reason: to reduce the nausea, indigestion and other gut-related side effects that are more likely to hit hard if you begin at a higher strength.

Some people do notice reduced appetite at 2.5 mg. Some lose a small amount of weight. Others feel little change at all. All of those experiences are normal, and none of them predict how you'll respond once the dose is properly titrated. The first four weeks are adjustment, not evidence of failure. Stopping because 2.5 mg "didn't work" is one of the most common reasons people miss out on the medicine's actual benefit.

If you're curious about what the 5 mg dose looks like as the next step, that page covers what to expect once titration begins.

What happens in the body during those first four weeks

Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) which together slow gastric emptying, signal fullness to the brain, and influence how the body manages blood sugar. At 2.5 mg, those pathways are being introduced to the medicine rather than running at full effect. Think of it as calibration rather than treatment proper.

The GI side effects that can come with tirzepatide (nausea, loose stools, reflux, constipation) are at their most likely in the early weeks and after each dose increase. Starting low limits their severity. Most people find the discomfort is mild and brief; it tends to settle within days to a couple of weeks as the body adapts. The NHS medicines page for tirzepatide sets out the full side-effect profile plainly if you want the complete list.

Storage matters from day one. The pen should be kept refrigerated at 2–8°C. For the exact room-temperature window that applies if you're travelling or the fridge is unavailable, the Patient Information Leaflet inside the box is the definitive source, the window is specific and varies by product batch, so we don't quote a figure here.

For a precise breakdown of how the 2.5 mg pen is structured (including what volume each dose represents) this page covers the ml measurement in detail.

Who starts on 2.5 mg and when the dose moves on

In the UK, Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Every qualifying patient begins at 2.5 mg, the dose does not change based on starting weight or urgency.

After four weeks at 2.5 mg, the standard next step is 5 mg, and titration continues roughly every four weeks from there up to the prescriber's target dose. At the 2.5 mg to 5 mg transition, some people notice the appetite effects become more noticeable for the first time. That is intentional, the 5 mg dose is where therapeutic benefit typically starts to land properly.

The prescriber decides the pace. If side effects are troublesome at any point, staying on the current dose for longer is clinically reasonable. Skipping ahead to speed up results is not, titration timing exists for safety, and deviating from it without clinical oversight can worsen side effects sharply. If you want to understand what the broader treatment journey looks like from the start, the Mounjaro overview page covers the full picture.

On the cost side of things, if you're weighing up what private treatment involves financially, our guide to Mounjaro pricing in the UK explains what legitimate private prescriptions include and why the headline price varies by provider. Worth a read before you compare quotes.

Practical things to know about the 2.5 mg KwikPen

The Mounjaro 2.5 mg pen is a pre-filled KwikPen made by Eli Lilly. It contains four doses, each delivered once weekly as a subcutaneous injection into the abdomen, thigh, or upper arm, rotating the site each time reduces local irritation. The pen's design means the dose is pre-set; you don't draw it up or adjust it. One pen, one month.

The 2.5 mg pen page goes into the mechanics in more detail, including how the injection mechanism works. If you're new to self-injection, it's worth reading before your first dose, most people find the process much simpler than they expected, and the needle is very fine.

Women taking oral contraceptives should add a non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption. This is stated in UK clinical guidance and is worth discussing with your prescriber before you begin, not after.

Mounjaro is a prescription-only medicine. Starting a conversation with a clinician is the right first move, our team at the free consultation page can walk through your situation and confirm whether it's clinically suitable for you.